文献速递认知障碍与痴呆

tau正电子发射断层扫描在认知症状患者诊断检查中的临床效用

Clinical Utility of Tau Positron Emission Tomography in the Diagnostic Workup of Patients With Cognitive Symptoms.
PubMed 文献 · JAMA Neurol · 2023-01-01

这项前瞻性队列研究纳入878例有认知主诉的患者,评估在包含脑脊液AD生物标志物的广泛诊断检查中加入tau PET的附加临床价值。tau PET使66例(7.5%)诊断改变、48例(5.5%)用药改变,并显著提高病因诊断确定性,尤其在Aβ阳性组效应量最大。作者建议tau PET的临床使用限于生物标志物提示Aβ阳性的群体。

要点

  • tau PET使7.5%患者诊断改变、5.5%患者用药改变。
  • tau PET后整体诊断确定性从6.9升至7.4(P<.001)。
  • Aβ阳性组效应量最大,Aβ正常组诊断无显著改变。

核心结论

  • 在已包含脑脊液AD生物标志物的广泛诊断检查中加入tau PET,与诊断和患者用药的显著改变相关。
  • 加入tau PET与潜在病因确定性显著增加相关,病因和诊断确定性的效应量在Aβ阳性组最大。
  • 作者建议tau PET的临床使用限于生物标志物提示Aβ阳性的群体。

研究设计与样本

  • 前瞻性队列研究(瑞典BioFINDER-2研究),2017年5月至2021年9月。
  • 878例有认知主诉的患者转诊至瑞典南部二级记忆门诊并招募入研究。
  • 共接触1269例连续参与者,391例不符合纳入标准或未完成研究。
  • 参与者接受基线诊断检查,包括临床检查、病史、认知测试、血液和脑脊液采样、脑磁共振成像和tau PET([18F]RO948)扫描。
  • 主要终点为PET前至PET后访视间诊断改变和AD药物治疗或其他药物治疗改变;次要终点为诊断确定性改变。

主要发现

  • 878例参与者平均年龄71.0(SD,8.5)岁,男性491例(56%)。
  • tau PET结果导致66例(7.5%)诊断改变和48例(5.5%)用药改变。
  • 整个数据集tau PET后整体诊断确定性从6.9(SD,2.3)升至7.4(SD,2.4);P<.001。
  • PET前诊断为AD的参与者确定性从7.6(SD,1.7)升至8.2(SD,2.0);P<.001。
  • tau PET阳性支持AD诊断的参与者确定性从8.0(SD,1.4)升至9.0(SD,0.9);P<.001。

临床怎么用

  • 作者建议tau PET的临床使用限于生物标志物提示Aβ阳性的群体。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: It is important to determine the added clinical value for tau positron emission tomography (PET) in the diagnostic workup of patients with cognitive symptoms before widespread implementation in clinical practice. OBJECTIVE: To prospectively study the added clinical value of PET detecting tau pathology in Alzheimer disease (AD). DESIGN, SETTING, AND PARTICIPANTS: This prospective cohort study (Swedish BioFINDER-2 study) took place from May 2017 through September 2021. A total of 878 patients with cognitive complaints were referred to secondary memory clinics in southern Sweden and then recruited to the study. In total, 1269 consecutive participants were approached, but 391 did not meet inclusion criteria or did not complete the study. EXPOSURES: Participants underwent a baseline diagnostic workup, including clinical examination, medical history, cognitive testing, blood and cerebrospinal fluid sampling, magnetic resonance imaging of the brain, and a tau PET ([18F]RO948) scan. MAIN OUTCOMES AND MEASURES: The primary end points were change in diagnosis and change in AD drug therapy or other drug treatment between the pre- and post-PET visits. A secondary end point was the change in diagnostic certainty between the pre- and post-PET visits. RESULTS: A total of 878 participants with a mean age of 71.0 (SD, 8.5) years (491 male [56%]) were included. The tau PET result led to a change in diagnoses in 66 participants (7.5%) and a change in medication in 48 participants (5.5%). The study team found an association with overall increased diagnostic certainty after tau PET in the whole data set (from 6.9 [SD, 2.3] to 7.4 [SD, 2.4]; P < .001). The certainty was higher in participants with a pre-PET diagnosis of AD (from 7.6 [SD, 1.7] to 8.2 [SD, 2.0]; P < .001) and increased even further in participants with a tau PET positive result supporting an AD diagnosis (from 8.0 [SD, 1.4] to 9.0 [SD, 0.9]; P < .001). The association with tau PET results had the largest effect sizes in participants with pathological amyloid-β (Aβ) status, whereas no significant change in diagnoses was seen in participants with normal Aβ status. CONCLUSIONS AND RELEVANCE: The study team reported a significant change in diagnoses and patient medication when tau PET was added to an already extensive diagnostic workup that included cerebrospinal fluid AD biomarkers. Including tau PET was associated with a significant increase in certainty of underlying etiology. The effect sizes for certainty of etiology and diagnosis were largest in the Aβ-positive group and the study team suggests that clinical use of tau PET be limited to populations with biomarkers indicating Aβ positivity.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Smith R, Hägerström D, Pawlik D, et al. Clinical Utility of Tau Positron Emission Tomography in the Diagnostic Workup of Patients With Cognitive Symptoms. JAMA Neurol. 2023. PMID: 37213093. doi:10.1001/jamaneurol.2023.1323

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。